AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00205166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine 200 mg po
Study NCT01075776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP)
Description: 360 pmol/min for 15 minutes intra-arterially
Study NCT01075776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride 0.9% intra-arterially 0.5ml/min
Study NCT01075776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: 2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Study NCT01075776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: 2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Study NCT02366871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral apixaban
Description: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
Study NCT02366871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous enoxaparin
Description: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
Study NCT03607318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iASIST
Description: Integrated Alcohol and Suicide Intervention for Suicidal Teens
Study NCT03607318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iASIST
Description: Integrated Alcohol and Suicide Intervention for Suicidal Teens
Study NCT01838876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
Study NCT01838876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
Study NCT01882452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Specificity Training
Description: This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
Study NCT01882452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Support
Description: The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
Study NCT00580320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine and bortezomib
Description: Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
Study NCT02935920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized, tailored follow-up program
Description: Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
Study NCT00325637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilnidipine
Description: Cilnidipine 10\~20mg, qd, po for 4 weeks.
Study NCT03980678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Rich Algae
Description: Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains \~13.1% Calcium, \~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
Study NCT03980678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange flavoured water with maltodextrin as the placebo
Description: Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
Study NCT01545336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg tablet to be taken 1 time daily
Study NCT01545336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg tablet to be taken 1 time daily
Study NCT00956202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
Study NCT00956202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
Study NCT00657020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge
Study NCT00956202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and day 21
Study NCT00521183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochlor
Description: The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
Study NCT00521183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine
Description: A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
Study NCT00521183 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
Study NCT04297592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: 500 mg oral tablet, 4 times daily for 7 days
Study NCT04297592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg oral tablet, 2 times daily for 7 days
Study NCT04297592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefadroxil
Description: 500 mg oral tablet, 2 times daily for 7 days
Study NCT02698293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: orally, 40 mg/kg 4-6 hours prior to light application
Study NCT02698293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol)
Description: Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
Study NCT02698293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therpay
Description: Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter.
Study NCT03101020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Visceral Manipulation
Description: Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
Study NCT03101020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care physiotherapy
Description: The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
Study NCT03101020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care physiotherapy
Description: The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
Study NCT03101020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Visceral Manipulation
Description: The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
Study NCT03359746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: Medication for treatment of patient
Study NCT03120611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercise
Description: Game developed by the Kinect, adapted to the lying position of participants.
Study NCT03120611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise intradialysis
Description: Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
Study NCT02933814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine
Description: Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
Study NCT02329717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI 05204
Description: PBI 05204 daily dosing
Study NCT00844311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: 150 iu/day of rFSH
Study NCT00844311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: 150 iu/day of rFSH
Study NCT00844311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: 50 iu/day of hCG from stimulation day 1
Study NCT00844311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: 100 iu/day of hCG from stimulation day 1
Study NCT00844311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: 150 iu/day of hCG from stimulation day 1
Study NCT01072591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-578
Description: intravenous infusion, once
Study NCT01072591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MEDI-578
Description: Intravenous infusion, once
Study NCT02049216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible tape
Description: Flexible, elasticised, adhesive athletic tape
Study NCT02049216 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fixomull
Study NCT02049216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in both groups will be prescribed a home exercise program to complete.
Study NCT02049216 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Participants in both groups will be prescribed a home exercise program to complete.
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 2mg/ml
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 1mg/ml
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 0.5 mg/ml
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 µl of water will be applied to a previously determined area on the volar forearm followed by a prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with 1 SPT
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with 5 SPT
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 5 prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with 25 SPT
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 25 prick through the drop
Study NCT04197440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAM8-22 with inactivate cowhage spicules
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study NCT01963234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seva
Description: Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
Study NCT01192815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally or via gastronomy tube
Study NCT01192815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01192815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field.
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Optional ancillary studies
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Optional correlative studies
Study NCT01192815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Optional correlative studies
Study NCT02287077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
Study NCT03444584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
Study NCT03444584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous dose of placebo matched to MEDI0382.
Study NCT03444584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaglifozin
Description: Oral dose of dapaglifozin 10 mg tablet.
Study NCT03444584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapaglifozin
Description: Oral dose of dapaglifozin 10 mg tablet.
Study NCT03444584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral dose of metformin tablet (maximum tolerated dose \[MTD\] > 1 g).
Study NCT03444584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Oral dose of metformin tablet (maximum tolerated dose \[MTD\] > 1 g).
Study NCT03211507 — intervention group
Intervention type: OTHER
Intervention: Computer-assisted telephone interview
Description: Occupational history
Study NCT03211507 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Description: To include analysis of known susceptibility markers
Study NCT03350919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training in the blind field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
Study NCT03698500 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Removal of blood
Description: 10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw